INTI · Inhibitor Therapeutics, Inc.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval.

These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan.

These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

The common stock options were issued to the Reporting Person on March 16, 2024 pursuant to the Issuer's 2014 Equity Incentive Plan. The common stock options vested immediately.

Grant from the company for no consideration

These shares represent 25,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.

Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC.

Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC.

Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares.

Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC.

Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares.

Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC.

Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares.

On January 15, 2021, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 2,240,488 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock.

These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer.

On July 15, 2020, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 3,189,688 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock.

These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer.